Pituitary neuroendocrine tumors treated with stereotactic radiosurgery
SRS is a highly effective modality for recurrent or residual pitNETs. This study observed a local control of 100% with no cases of optic toxicities after a median follow-up of 4.7 years. These observed findings suggest that dose de-escalation may be possible for future treatment of pitNETs.
Authors
- Dana Keilty (ORCID: https://orcid.org/0000-0001-6374-2755)
- Michael D. Cusimano (ORCID: https://orcid.org/0000-0002-9989-0650)
- Gelareh Zadeh (ORCID: https://orcid.org/0009-0009-2002-5313)
- Hye Suk Kim (ORCID: https://orcid.org/0000-0001-9262-3800)
- Derek S. Tsang (ORCID: https://orcid.org/0000-0002-9762-6901)
- Michael Yan (ORCID: https://orcid.org/0000-0002-8387-6563)
- Robert K. Heaton (ORCID: https://orcid.org/0000-0001-8274-3681)
- David Shultz (ORCID: https://orcid.org/0000-0001-8242-6555)
- Aristotelis Kalyvas (ORCID: https://orcid.org/0000-0002-0222-488X)
- Normand Laperrière (ORCID: https://orcid.org/0000-0001-8930-9650)
- Saira B. Alli
- David G. Payne
- Colin Faulkner
- Michel Sourour
Institutions
- St. Michael's Hospital (CA)
- University Health Network (CA)
- University of Toronto (CA)
- Toronto Western Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Unity Health Toronto
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1007/s11060-024-04864-3
- Citations
- 2
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.72